|
FY2023
12 months to Jun 30, 2023
|
FY2022
12 months to Dec 31, 2021
|
|
|---|---|---|
| Cash Flows from Operating Activities | ||
| Net loss | ||
| Change in fair value of warrant liabilities | ||
| Loss on initial issuance of private warrants | ||
| Interest earned on marketable securities held in Trust Account | ||
| Prepaid expenses | ||
| Accounts payable and accrued expenses | ||
| Due to related party | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation, amortization and impairment | ||
| Stock-based compensation | ||
| Earnout share stock-based compensation | ||
| Contra-revenue associated with warrant agreement (Refer to Note 2) | ||
| Noncash expense attributable to fair value liabilities assumed in Merger | ||
| Change in fair value of liability classified warrants | ||
| Change in fair value of warrants and convertible promissory notes | ||
| Amortization of debt discount and debt issuance costs | ||
| Paid-in-kind interest expense | ||
| Share and warrant cost on termination of convertible note agreement | ||
| Change in fair value of Unvested Sponsor Shares liability | ||
| Noncash lease expense | ||
| Loss on disposal off property and equipment | ||
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | ||
| Inventories | ||
| Deferred costs | ||
| Prepaid expenses and other current assets | ||
| Accounts payable | ||
| Accrued liabilities | ||
| Deferred revenue | ||
| Other long-term liabilities | ||
| Net cash used in operating activities | ||
| Cash Flows from Investing Activities | ||
| Purchase of property and equipment | ||
| Payments relating to capitalized software | ||
| Investment in non-affiliate | ||
| Net cash used in investing activities | ||
| Cash Flows from Financing Activities | ||
| Proceeds from the exercise of common stock options | ||
| Proceeds from the issuance of term loans | ||
| Payment of debt issuance costs | ||
| Payment of penalties and other costs on extinguishment of debt | ||
| Principal payments of financing obligations | ||
| Proceeds from the issuance of common stock | ||
| Advances from related parties | ||
| Payment of offering costs | ||
| Contributions from Merger and PIPE financing, net of transaction costs and other payments | ||
| Payments of deferred transaction costs | ||
| Net cash provided by financing activities | ||
| Net increase (decrease) in cash, cash equivalents and restricted cash | ||
| Cash – Beginning of year | ||
| Cash – End of year | ||
| Change in accretion for common stock subject to possible redemption | ||
| Cash, cash equivalents and restricted cash at beginning of period | ||
| Cash, cash equivalents and restricted cash at end of period | ||
| Supplemental Disclosure of Non-Cash Investing and Financing Activities | ||
| Capitalization of stock-based compensation expense to capitalized software | ||
| Issuance of warrants | ||
| Capital contribution from shareholder in conjunction with Credit Agreement | ||
| Issuance of warrants in conjunction with Credit Agreement | ||
| Issuance of warrants in conjunction with Lago Term Loan | ||
| Convertible note conversion to common stock | ||
| Reclassification of warrants from liabilities to equity | ||
| Recognition of liability classified warrants upon Merger | ||
| Recognition of Unvested Sponsor Shares liability | ||
| Forgiveness of PPP Loan | ||
| Right of use asset in exchange for operating lease liability |
Loading...
